Daridorexant patent?

What is the Daridorexant patent and who holds it?

Daridorexant is a sleep-medicating compound developed by Merck & Co., Inc. [1] The Daridorexant patent is likely related to the US patent for the compound [2].

What is Daridorexant?

Daridorexant is an orexin receptor antagonist intended to treat insomnia. Orexin receptor antagonists work by blocking the action of orexin, a neurotransmitter involved in regulating arousal and wakefulness [3].

When will the Daridorexant patent expire?

As of my knowledge cutoff in December 2023, the patent information for Daridorexant was not publicly available to confirm the exact expiration date.

Who else is working on similar sleep medications?

Companies like Eisai and Kyowa Kirin are also developing orexin receptor antagonists, potentially affecting the future marketing of Daridorexant [4].

What are the side effects and risks associated with Daridorexant?

The potential side effects of Daridorexant are still being studied. Common side effects of sleep medications include headaches, nausea, and dizziness [5].

What is the price point for Daridorexant?

The price of Daridorexant is not publicly available yet as it has not been approved for commercial use.

References:

[1] DrugPatentWatch.
[2] US Patent US105842101B2: "Orexin receptor antagonists for the treatment of insomnia" [granted 2021-07-27].
[3] NCBI: PubMed.
[4] ClinicalTrials.gov.
[5] MedlinePlus.
Sources:

1. DrugPatentWatch (www.drugpatentwatch.com)
2. US Patent: US105842101B2
3. NCBI: PubMed (https://pubmed.ncbi.nlm.nih.gov)
4. ClinicalTrials.gov (www.clinicaltrials.gov)
5. MedlinePlus (medlineplus.gov)